FDA Approved: IDHIFA — Original Application (Celgene Corporation)

View source ↗

Summary

FDA approves IDHIFA (enasidenib) in the original application for adult patients with relapsed or refractory acute myeloid leukemia harboring an IDH2 mutation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• IDHIFA (enasidenib)

Snippet

ORIG AP for IDHIFA (ENASIDENIB MESYLATE)